enGene Therapeutics Inc. (ENGN)

Over the past six months, enGene Holdings, Inc.'s stock (ENGN) has experienced fluctuations. As of March 27, 2026, the share price was $6.37, representing an increase of 42.19% from $4.48 on March 31, 2025, but has trended down by 1.85% to 11.33% depending on the specific measurement date. Key events include the completion of enrollment in the LEGEND Phase 2 trial, preliminary LEGEND trial data showing a 63% complete response rate at 3 months and a 62% complete response rate at 6 months, selection for the FDA's CDRP program, planned BLA submission in the second half of 2026, expansion of its debt facility with Hercules Capital, Inc. for up to $125 million, and a Q1 2026 net loss of approximately $29.8 million, or $0.44 per share, with a cash runway expected into the second half of 2028.

As a clinical-stage biotechnology company, enGene Holdings, Inc. does not exhibit typical demand seasonality for its products or services. The demand for detalimogene voraplasmid will be driven by clinical trial outcomes, regulatory approvals, and the medical need for treating non-muscle invasive bladder cancer, rather than seasonal patterns.

enGene Holdings, Inc. is a clinical-stage biotechnology company based in Montreal, Canada, focused on delivering therapeutics to mucosal tissues and other organs to mainstream genetic medicines. The company's primary product candidate is detalimogene voraplasmid (EG-70), a non-viral gene therapy for high-risk non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. The LEGEND trial is currently in Phase 2. Detalimogene is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) gene delivery platform.

enGene Holdings, Inc. is headquartered in Saint-Laurent, Quebec, Canada.

enGene Holdings, Inc.'s brand reputation in the past year appears to be generally positive within the biotechnology investment community, driven by its clinical progress and financial positioning. The company has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.80. Despite some price target adjustments, the overall sentiment remains cautiously optimistic, supported by promising clinical data for detalimogene voraplasmid in NMIBC and a strong financial position. The company's acceptance into the FDA's CDRP program and the planned BLA submission for detalimogene are also positive indicators.

enGene Holdings, Inc. has a diverse ownership structure. Institutional shareholders own approximately 75.55% to 87.63% of the company's shares, private equity firms hold around 38% of the shares, while institutional ownership is about 35%, and insiders own approximately 24.45% to 28.36% of the company. Major institutional owners include Fcpm Iii Services B.v., Perceptive Advisors Llc, VR Adviser, LLC, Deep Track Capital, LP, Cormorant Asset Management, LP, Blue Owl Capital Holdings LP, Siren, L.L.C., Braidwell Lp, Nextech Invest, Ltd., and Janus Henderson Group Plc. Forbion Growth Opportunities Fund I Cooperatief Ua is a significant individual shareholder, owning 10.15% of the company's shares.